COVID-19 in Primary Care, Protecting the Most Vulnerable

30 May 2020, 10:00 to 12:00

3rd IPCRG Clinical Practice Webinars & Abstract Presentations

COVID-19 in Primary Care, Protecting the Most Vulnerable

Saturday 30 May 2020, 1000-1200hrs BST 

The COVID-19 pandemic is testing the resilience of primary care and the populations we look after. COVID-19 is hitting vulnerable groups even harder as it exacerbates pre-existing vulnerabilities and creates new ones.  Different countries are at different stages of their journey with COVID-19 and have used different systems & actions to identify and protect their most vulnerable.  

Therefore, how we protect our most vulnerable in our population is the topic of the third in our series of IPCRG webinars. Giving a perspective from their countries, we are delighted to be joined by Hanna Sandelowsky from Sweden and Chunhua Chi from China. 

This was followed by some of the top-ranking abstracts that would have been presented at our world conference in Dublin this week, giving researchers a truly international platform and opportunity for peer review. 

Past Conference COVID COVID-19 WEBINAR

We are grateful to Astra Zeneca for their support for this webinar.

Respiratory & Immunology is one of AstraZeneca’s three therapy areas and is a key growth driver for the Company.

AstraZeneca is an established leader in respiratory care, and its inhaled and biologic medicines reached more than 53 million patients in 2019. Building on a 50-year heritage, the Company aims to transform the treatment of asthma and COPD by focusing on earlier biology-led treatment, eliminating preventable asthma attacks, and removing COPD as a top-three leading cause of death. The Company’s early respiratory research is focused on emerging science involving immune mechanisms, lung damage and abnormal cell repair processes in disease and neuronal dysfunction.

With common pathways and underlying disease drivers across respiratory and immunology, AstraZeneca is following the science from chronic lung diseases to immunology-driven disease areas. The Company’s growing presence in immunology is focused on five mid- to late-stage franchises with multi-disease potential, in areas including rheumatology (including lupus), dermatology, gastroenterology, and systemic eosinophilic-driven diseases. AstraZeneca’s ambition in Respiratory & Immunology is to achieve disease modification and durable remission for millions of patients worldwide.